AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Advexin vaccine therapy to begin phase I/II.
2004 JAN 1 - (NewsRx.com & NewsRx.net) -- Introgen Therapeutics, Inc., (INGN) announced that its vaccine therapy, INGN 225, will be evaluated at two U.S. cancer centers in a phase I/II study to treat patients with advanced breast cancer.
The trial will be conducted by Drs. Kenneth H. Cowan and Elizabeth Reed at the University of Nebraska Medical Center in Omaha, Nebraska. The H. Lee Moffitt Cancer Center in Tampa, Florida will prepare the vaccine and participate in immunologic evaluations. Enrollment will begin with patients with invasive breast cancer who will receive chemotherapy, in addition to the INGN 225 vaccine.
The INGN 225 vaccine was developed based on work by Dr. Dmitry Gabrilovich, associate professor of oncology at the Moffitt Cancer Center, and Dr. David Carbone, professor of oncology at The Vanderbilt-Ingram Cancer Center, and is exclusively licensed to Introgen Therapeutics.
Gabrilovich said, "A goal of cancer immunologists is the development of viable cancer vaccines. As we progress into human trials for different types of cancer, we are moving closer to achieving that goal. With the high incidence and ...
- Introgen Awarded $492,600 Grant From the National Cancer Institute to Evaluate...
- Press release article from: PR Newswire January 22, 2002 700+ words
...Texas M. D. Anderson Cancer Center, and principal investigator...preclinical development of INGN 241, (Adenoviral-mda7...Introgen and M. D. Anderson Cancer Center that evaluate the therapeutic...mda7 in human melanoma. INGN 241 is a modified adenoviral...
- Introgen's INGN 241 in Combination With Tarceva Inhibits Tumor Growth.
- Press release article from: PR Newswire June 4, 2006 700+ words
...Texas M. D. Anderson Cancer Center show that the combination of Introgen's INGN 241 and Tarceva(R...encouraging findings of INGN 241 treatment in the...with M. D. Anderson Cancer Center to commercialize products...development program with INGN 241 in combination with...
- Introgen's INGN 241 Effective Against Multiple Cancers in Preclinical Studies.
- Press release article from: PR Newswire June 6, 2005 700+ words
INGN 241 Studies in Breast, Pancreatic...the anti-cancer activity of INGN 241 alone or in combination...University of Texas M.D. Anderson Cancer Center, the studies show that expression...gene, the active component of INGN 241, increases cancer cell...
- Preclinical Studies Identify Novel Approach for Enhancing the Anticancer...
- Press release article from: Business Wire April 25, 2007 700+ words
...tumor killing effects of INGN 241 in cell culture and...Texas M. D. Anderson Cancer Center conducted the studies...the active component of INGN 241, activates NF...Surgery at M. D. Anderson Cancer Center and principal author...
- Introgen's INGN 241 Kills Chemotherapy-Resistant Cancer Cells.
- Press release article from: PR Newswire April 4, 2006 700+ words
...Texas M. D. Anderson Cancer Center (MDACC) today reported...the active component of INGN 241, effectively kills...encouraging findings of INGN 241 treatment in the...with M. D. Anderson Cancer Center to commercialize products...clinical development of INGN 241 for cancers ...
- Introgen's INGN 241 Gene Therapeutic Suppresses Growth of Lung Cancer Tumors.
- Press release article from: PR Newswire December 13, 2001 700+ words
...in preclinical studies that INGN 241, its mda-7 gene drug...University of Texas M. D. Anderson Cancer Center. Dr. Ramesh commented...nutrients. This suggested that INGN 241 might also play a role in...we were pleased to find that INGN 241 is also a very potent angiogenic...
- Introgen's p53 Immunotherapy INGN 225 Begins Randomized, Controlled Clinical...
- Press release article from: Business Wire February 13, 2008 700+ words
...Therapeutics, Inc. (NASDAQ:INGN) and Moffitt Cancer Center today announced that...controlled study of INGN 225, Introgen's immunotherapy...laboratory to generate the INGN 225 immunotherapy. About H. Lee Moffitt Cancer Center & Research Institute...
- Positive Results Reported From Introgen's Phase 2 Trial of INGN 225...
- Press release article from: PR Newswire February 21, 2006 700+ words
...clinical evaluation of INGN 225," said co...H. Lee Moffitt Cancer Center & Research...H. Lee Moffitt Cancer Center & Research...responses following INGN 225 administration...Scientific Affairs. INGN 225 is also being...H. Lee Moffitt Cancer Center & ...
Source: HighBeam Research, Advexin vaccine therapy to begin phase I/II.